Tango Therapeutics (TNGX) Stock Price, News & Analysis

Company Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $3.70 to $3.98
• 50-Day Range: $2.83 to $7.70
• 52-Week Range: $2.70 to $13.01
• Volume: 273,350 shs
• Average Volume: 1.00 million shs
• Market Capitalization: $400.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.14
• Consensus Rating: Buy

Tango Therapeutics Stock Analysis - MarketRank™

Tango Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 373rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Tango Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tango Therapeutics is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tango Therapeutics is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tango Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.40% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tango Therapeutics has recently decreased by 21.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tango Therapeutics does not currently pay a dividend.

Dividend Growth

Tango Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.40% of the float of Tango Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Tango Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tango Therapeutics has recently decreased by 21.70%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.20

News Sentiment

Tango Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tango Therapeutics insiders have sold 26,930.92% more of their company's stock than they have bought. Specifically, they have bought $74,000.00 in company stock and sold $20,002,882.00 in company stock.

Percentage Held by Insiders

Only 6.30% of the stock of Tango Therapeutics is held by insiders.

Percentage Held by Institutions

78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TNGX Stock Analysis - Frequently Asked Questions

How have TNGX shares performed this year?

Tango Therapeutics' stock was trading at $9.90 at the beginning of the year. Since then, TNGX shares have decreased by 60.7% and is now trading at $3.89.
View the best growth stocks for 2024 here.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its earnings results on Wednesday, August, 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10. The business had revenue of $19.88 million for the quarter, compared to the consensus estimate of $7.39 million. Tango Therapeutics had a negative net margin of 284.42% and a negative trailing twelve-month return on equity of 49.64%.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' top institutional shareholders include TRV GP IV LLC (15.74%), FMR LLC (8.73%), Southpoint Capital Advisors LP (4.65%) and State Street Corp (2.16%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Boxer Capital Management, Llc, Mva Investors, Llc, Daniella Beckman, Douglas Barry and Mace Rothenberg.
View institutional ownership trends.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Tango Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/07/2024
• Today: 12/03/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TNGX
• CUSIP: N/A
• CIK: 1819133
• Web: www.tangotx.com
• Phone: 857-320-4900
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.14
• High Stock Price Target: $19.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +252.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-101,740,000.00
• Net Margins: -284.42%
• Pretax Margin: -283.95%
• Return on Equity: -49.64%
• Return on Assets: -32.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.00
• Quick Ratio: 8.00

Sales & Book Value

• Annual Sales: $36.53 million
• Price / Sales: 10.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.48 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 107,420,000
• Free Float: 100,651,000
• Market Cap: $400.68 million
• Optionable: Optionable
• Beta: 0.75